This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Cimetropium
- DrugBank Accession Number
- DB09271
- Background
Cimetropium is a semi-synthetic belladonna alkaloid and derivative of scopolamine. It is a potent antimuscarinic and an effective antispasmodic drug. It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada.
- Type
- Small Molecule
- Groups
- Experimental, Investigational
- Structure
Structure for Cimetropium (DB09271)
- Weight
- Average: 358.457
Monoisotopic: 358.201284806 - Chemical Formula
- C21H28NO4
- Synonyms
- Cimetropium cation
- Cimetropium ion
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetylcholine Acetylcholine may decrease the anticholinergic activities of Cimetropium. Aclidinium The risk or severity of adverse effects can be increased when Aclidinium is combined with Cimetropium. Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Cimetropium. Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Cimetropium. Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cimetropium. Aripiprazole The risk or severity of adverse effects can be increased when Aripiprazole is combined with Cimetropium. Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Cimetropium. Belladonna The risk or severity of adverse effects can be increased when Belladonna is combined with Cimetropium. Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Cimetropium. Bethanechol Bethanechol may decrease the anticholinergic activities of Cimetropium. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Cimetropium bromide 0C7M5WE60Q 51598-60-8 WDURTRGFUGAJHA-GSWUYBTGSA-M
Categories
- ATC Codes
- A03BB05 — Cimetropium bromide
- Drug Categories
- Alimentary Tract and Metabolism
- Alkaloids
- Autonomic Agents
- Aza Compounds
- Azabicyclo Compounds
- Belladonna Alkaloids, Semisynthetic, Quaternary Ammonium Compounds
- Belladonna and Derivatives, Plain
- Drugs for Functional Gastrointestinal Disorders
- Parasympatholytics
- Peripheral Nervous System Agents
- Tropanes
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Hydroxy acids and derivatives
- Sub Class
- Beta hydroxy acids and derivatives
- Direct Parent
- Beta hydroxy acids and derivatives
- Alternative Parents
- Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Azacyclic compounds / Oxacyclic compounds / Dialkyl ethers / Epoxides show 7 more
- Substituents
- Alcohol / Amine / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Beta-hydroxy acid / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Dialkyl ether show 21 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1N3H74AYTK
- CAS number
- 150521-16-7
- InChI Key
- QVVOZYKELHAIPX-WVHCHWADSA-N
- InChI
- InChI=1S/C21H28NO4/c1-22(11-13-7-8-13)17-9-15(10-18(22)20-19(17)26-20)25-21(24)16(12-23)14-5-3-2-4-6-14/h2-6,13,15-20,23H,7-12H2,1H3/q+1/t15-,16-,17-,18+,19-,20+,22?/m1/s1
- IUPAC Name
- (1R,2R,4S,5S,7S)-9-(cyclopropylmethyl)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azatricyclo[3.3.1.0^{2,4}]nonan-9-ium
- SMILES
- [H][C@](CO)(C(=O)O[C@@]1([H])C[C@@]2([H])[C@]3([H])O[C@]3([H])[C@@]([H])(C1)[N+]2(C)CC1CC1)C1=CC=CC=C1
References
- General References
- Scarpignato C, Bianchi Porro G: Cimetropium bromide, a new antispasmodic compound: pharmacology and therapeutic perspectives. Int J Clin Pharmacol Res. 1985;5(6):467-77. [Article]
- External Links
- KEGG Drug
- D07099
- PubChem Compound
- 20054871
- PubChem Substance
- 310265166
- ChemSpider
- 28529144
- ChEBI
- 135516
- ChEMBL
- CHEMBL2110773
- ZINC
- ZINC000100014304
- Wikipedia
- Cimetropium_bromide
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Unknown Status Diagnostic Colonoscopy 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, solution Solution / drops Oral Suppository Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00244 mg/mL ALOGPS logP 0.45 ALOGPS logP -2.5 Chemaxon logS -5.2 ALOGPS pKa (Strongest Acidic) 15.15 Chemaxon pKa (Strongest Basic) -2.7 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 59.06 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 107.58 m3·mol-1 Chemaxon Polarizability 38.5 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created at October 28, 2015 19:38 / Updated at June 12, 2020 16:52